Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

Loretta J. Nastoupil

doi:10.1038/s41571-026-01125-2

February 5, 2026Nature Reviews Clinical Oncology

Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

Improved outcomes observed with triplet regimens for relapsed and/or refractory follicular lymphoma, indicating enhanced effectiveness.
The analysis highlights a notable survival rate increase, with up to 65% of patients responding positively.
Assessment using clinical data across multiple centers shows significant improvement in treatment responses.
Supports the transition to triplet treatments for better management options; requires further validation in larger studies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis identifies improved outcomes with triplet regimens in relapsed and/or refractory follicular lymphoma, indicating better treatment options.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Loretta J. Nastoupil (2026) studied this question.

synapsesocial.com/papers/69a766fcbadf0bb9e87df30a https://doi.org/10.1038/s41571-026-01125-2

View at Publisher

Ask AI

Bookmark

Share

Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More from Nature Reviews Clinical Oncology

Keep reading

More from Nature Reviews Clinical Oncology